Anticancer Mechanisms

The main mechanistic routes through which apigenin shows anticancer activity in preclinical models.

Apigenin’s anticancer biology is broad rather than single-target. The mechanisms below are the most repeated, cross-tumour-relevant, and clinically meaningful across the literature.

1. BCL-2 family modulation — MCL-1 and BCL-xL

This is the mechanism with the clearest place in resistance biology.

BCL-2 family proteins such as BCL-2, BCL-xL, and MCL-1 act as anti-apoptotic gatekeepers. Overexpression is one of the common ways cancer cells survive treatment stress and resist chemotherapy. MCL-1 matters especially because it often becomes the final escape protein when BCL-2 and BCL-xL are already under pressure.

Apigenin suppresses both BCL-xL and MCL-1 by inhibiting STAT3 phosphorylation, which normally supports their expression. When STAT3 falls, BCL-xL and MCL-1 fall with it. That shifts the balance toward pro-apoptotic proteins such as BAX and BAK, promotes mitochondrial permeabilisation, and activates caspases.

This has been shown in colon cancer, ovarian cancer, and other models. It is directly relevant to therapy-resistant states.

In the context of a layered Senolytic Pulse Protocol, this mechanism matters because residual stressed or senescent-like cells can shift toward MCL-1 dependence after earlier pressure on BCL-xL and BCL-2. Apigenin’s STAT3-linked pressure on MCL-1 is designed to close that escape route.

This is not human-proven. It is, however, one of the clearest mechanistic rationales in the flavone literature.

2. STAT3 and NF-κB suppression

STAT3 and NF-κB are master regulators of survival, inflammation, and immune evasion. Both are frequently constitutively active in cancer.

Apigenin suppresses phosphorylation of both pathways in multiple cancer models. That reduces downstream targets including BCL-2 family proteins, COX-2, VEGF, and pro-inflammatory cytokines. In colitis-associated colon cancer models, apigenin reduced phosphorylation of both NF-κB and STAT3 in tumour tissue.

This dual suppression links the direct anticancer signal to the broader inflammatory and senescence-related terrain. For the wider senescence context, see Senescence — The Second Escape Route.

3. PI3K/AKT/mTOR pathway inhibition

The PI3K/AKT/mTOR pathway regulates growth, survival, and metabolic activity. Constitutive activation is common in many cancers and strongly linked to treatment resistance.

Apigenin inhibits PI3K/AKT signalling, which can suppress mTOR, reduce pro-survival gene expression, and trigger apoptosis or autophagy depending on context. In prostate cancer models, Akt inactivation caused dephosphorylation of BAD, releasing a normally restrained pro-apoptotic signal and driving apoptosis. This effect was confirmed both in vitro and in xenograft models.

4. NRF2 / Redox Dual Action

What NRF2 is and why it matters here

NRF2 (nuclear factor erythroid 2-related factor 2) is the cell’s master switch for antioxidant defence. Under oxidative stress, NRF2 detaches from its inhibitor KEAP1, moves into the nucleus, and activates the antioxidant response element (ARE). That switches on a battery of protective enzymes including HO-1, NQO1, and glutamate-cysteine ligase. The result is lower ROS, less lipid peroxidation, and better cell survival under stress.

In healthy tissue, that is desirable. In established cancer, it can become a problem. Constitutively overactive NRF2 is now well documented as a driver of tumour progression, metabolic reprogramming, cancer stem-cell self-renewal, drug efflux, and chemoresistance across multiple tumour types including lung, liver, and pancreatic cancer.

This is the core double-edged nature of NRF2 in oncology. It can protect normal tissue, while also supporting tumour survival and resistance in the wrong context.

Where apigenin activates NRF2

In non-cancer and normal-tissue models, apigenin consistently activates the NRF2-ARE axis.

In retinal pigment epithelial ARPE-19 cells, apigenin at 200–400 µM significantly increased NRF2 nuclear translocation and raised HO-1, NQO1, and GCLM at both mRNA and protein level. These effects were abolished when NRF2 was silenced with siRNA, confirming NRF2 as the essential pathway rather than a bystander.
In rat liver exposed to cyclophosphamide, apigenin protected liver tissue by upregulating NRF2 and HO-1, reducing ROS, MDA, and inflammatory cytokines, and decreasing treatment-induced DNA damage and apoptosis in normal hepatocytes.
In mouse skin epidermal cells, apigenin reactivated NRF2 signalling that had been silenced by epigenetic DNA methylation changes, restoring antioxidant defence through CpG demethylation at the NRF2 promoter.
In metabolic disease models including high-fructose and NAFLD settings, apigenin promoted NRF2 nuclear accumulation and increased HO-1 and NQO1 expression, reducing oxidative and inflammatory organ damage.

The practical implication is clear. In normal tissue under chemical, metabolic, or treatment-related stress, apigenin tends to reinforce antioxidant capacity.

Where apigenin suppresses NRF2

In cancer cells where NRF2 is constitutively overactive and driving chemoresistance, apigenin can behave differently and act as an NRF2 suppressor.

In doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells, a non-toxic dose of apigenin reduced NRF2 expression at both mRNA and protein level by downregulating the PI3K/Akt pathway, which normally stabilises NRF2 and protects it from degradation. The downstream effect was lower expression of NRF2-regulated drug-efflux genes and detoxification enzymes, with significantly higher intracellular doxorubicin accumulation.
In a xenograft model from the same line of work, apigenin plus doxorubicin inhibited tumour growth, reduced proliferation, and increased apoptosis more than doxorubicin alone. This remains one of the most mechanistically direct chemosensitisation papers in the apigenin literature.
Separate review-level evidence also places apigenin alongside luteolin and brusatol as a natural NRF2 inhibitor in NRF2-addicted tumours, especially where constitutive activation is driven by KEAP1 or NRF2 mutation rather than external stress.

The ferroptosis intersection

NRF2 is also a central gatekeeper of ferroptosis. By upregulating GPX4 and SLC7A11, constitutively active NRF2 helps cancer cells suppress lipid peroxidation and resist ferroptotic death.

In cancer cells that depend on NRF2 for ferroptosis resistance, apigenin’s ability to suppress NRF2 through PI3K/Akt could lower the ferroptosis threshold and increase vulnerability to ferroptosis-directed co-interventions. At present, this remains a mechanistic connection rather than a fully characterised combined effect in a single published cancer model, but it is biologically coherent and worth tracking.

NRF2: friend or foe in cancer — a short explainer

NRF2 as friend — early or preventive context
When cells are under stress but have not yet become cancerous, NRF2 works protectively. It clears ROS before they can damage DNA, reduces chronic inflammation that can support tumour initiation, and helps normal cells withstand treatment-related toxicity. In this setting, supporting NRF2 activity is broadly favourable.

NRF2 as foe — established cancer context
In many established cancers, NRF2 becomes locked into persistent activation, either through KEAP1 loss, direct NRF2 alteration, or oncogenic signalling from pathways such as KRAS and MYC. In that state, NRF2 does the same jobs it always did, but now in service of the tumour. It clears the ROS that therapy is trying to exploit, supports efflux transporters, preserves metabolic flexibility, and helps cancer cells resist apoptosis.

Why apigenin’s dual action matters
The key question is not whether apigenin activates or inhibits NRF2, but in what context. Current evidence suggests activation in normal and metabolically stressed tissue, and suppression in at least some NRF2-addicted cancer models. Whether that tissue selectivity is consistent across tumour types, and how it behaves in humans using liposomal apigenin during active treatment, remains unknown.

5. Cell-cycle arrest at G2/M

Apigenin repeatedly arrests cancer cells in the G2/M phase of the cell cycle. That has been documented across colorectal, prostate, melanoma, and other cell lines.

The mechanism involves downregulation of cyclin B1 and CDK1, plus upregulation of the CDK inhibitor p21. Cell-cycle arrest is often paired with p53 stabilisation and pro-apoptotic signalling.

6. Anti-metastatic effects

A systematic review of six animal studies found statistically significant reductions in metastatic nodule counts across melanoma, ovarian, liver, prostate, and intestinal cancer models.

Mechanisms include:

suppression of epithelial-mesenchymal transition through higher E-cadherin and lower vimentin, N-cadherin, Snail, and Slug
inhibition of MMP2 and MMP9, which degrade extracellular matrix and support invasion
anti-angiogenic effects through suppression of VEGF, SPOCK1, and VCAM-1

7. Tumour metabolism — PKM2 and glycolysis

PKM2 is a metabolic enzyme heavily used by glycolytic tumour cells, especially in colorectal cancer. Apigenin suppresses PKM2 at both mRNA and protein level by blocking the β-catenin/c-Myc/PTBP1 axis.

That interferes with the metabolic advantage of highly glycolytic tumours and adds a distinct non-apoptotic pressure point.

8. Ferroptosis

Apigenin also has emerging evidence as a ferroptosis-modulating compound. That adds a third regulated cell-death route beyond apoptosis and autophagy.

In human endometrial carcinoma Ishikawa cells, apigenin increased iron-dependent lipid peroxidation, depleted antioxidant defences, and triggered ferroptotic cell death in vitro, with matching tumour-growth inhibition in vivo. Ferroptosis inhibitors blunted the effect, confirming that ferroptosis was involved.

In multiple myeloma NCI-H929 cells, apigenin induced a mixed death response involving apoptosis, autophagy, and ferroptosis, again with clear ROS and lipid-peroxidation signatures and sensitivity to ferroptosis blockade.

That multiple-myeloma signal was also supported by work showing direct cytotoxicity against myeloma cell lines and primary myeloma cells, with the associated mechanisms extending beyond apoptosis alone.

These data are early and still cell-line-centred. They nevertheless suggest that apigenin can, under the right conditions, push iron-rich and oxidatively stressed cancer cells into ferroptosis rather than relying only on classic mitochondrial apoptosis.